|
|
| |
| Scientific Program |
 |
|
|
Thursday, October 18, 2012 |
|
14:00-16:00 |
|
|
HEPATITIS C – ADDRESSING THE CHALLENGE |
|
Moderators: Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel |
|
14:00-14:05 |
Chairpersons Congress Welcome Address |
|
14:05-14:30 |
HCV in 2020: Any cases left? Rafael Esteban, Spain  |
|
14:30-14:35 |
Discussion |
|
14:35-15:00 |
HCV vaccine: Where do we stand? Ulrich Spengler, Germany  |
|
15:00-15:05 |
Discussion |
|
Interferon-free HCV therapy: Are we getting there? |
|
15:05-15:25 |
No: Graham Foster, UK |
|
15:25-15:45 |
Yes: Heiner Wedemeyer, Germany |
|
15:45-16:00 |
Discussion |
|
|
|
16:00-17:30 |
Pipeline Showcase: New Drugs on the Horizon HALL A |
|
Chairperson: Jonathan M. Schapiro , Israel |
| 16:00-16:05 |
Introduction |
| 16:05-16:20 |
Strategies towards cure of HCV infection: a personalized approach
Heiner Wedemeyer, Germany
Presentation Supported by BMS |
| 16:20-16:35 |
Combination DAA Therapy for Hepatitis C
Douglas Mayers, USA
Presentation Supported by Idenix |
| 16:35-16:50 |
Host targeting therapies for the treatment of Hepatitis C
Claudio Avila, Switzerland
Presentation Supported by Novartis |
| 16:50-17:05 |
The ANNAPURNA study: Evaluating the Combination of Setrobuvir, Danoprevir/r and Ribavirin With or Without Mericitabine in Patients With Chronic Hepatitis C
Eckart Schott, Germany
Presentation Supported by Roche |
| 17:05-17:20 |
Silibinin dihydrogensuccinate for the prevention of hepatitis C recurrence after liver transplantation and treatment of non-responders to anti-HCV therapy,
Lucio Rovati, Italy
Presentation Supported by Rottapharm | Madaus |
| 17:20-17:30 |
Panel Discussion |
|
|
|
17:30-18:00 |
Coffee Break and Poster Exhibition |
|
|
|
18:00-19:15 |
|
Janssen Satellite Symposium
DAAs: Raising Standards in Patient Care |
HALL A | |
|
18:00-18:05 |
Welcome and introduction: Thomas Berg , Germany |
|
18:05-18:25 |
Practical recommendations in the era of DAAs: Vlad Ratziu , France |
|
18:25-18:45 |
Managing DAA treatment in HIV-HCV co-infected patients: Massimo Puoti, Italy |
|
18:45-19:05 |
Understanding our patients: challenging clinical cases: Marina Berenguer, Spain |
|
|
Summary and key learnings: Thomas Berg , Germany |
|
|
|
19:15-20:30 |
Welcome Reception, Sponsored by Abbott |
|
|
|
|
HCV DIRECT ACTING ANTIVIRALS: HOW HAVE THE TREATMENT PARADIGMS CHANGED |
|
Moderators: Stefan Zeuzem, Germany & Eckart Schott, Germany |
|
09:00-09:05 |
Overview of HCV sessions by HCV Program Director
Stefan Zeuzem , Germany |
|
|
Direct Antivirals: How have the treatment paradigms changed? |
|
|
Moderators Introduction |
|
HCV Direct Acting Antivirals: |
|
09:10-09:30 |
In treatment naïve: Stanislas Pol, France |
|
09:30-09:50 |
In treatment experienced: Thomas Berg, Germany |
|
09:50-10:10 |
Toxicity management: Christoph Hezode, Paris |
|
10:10-10:40 |
Drug-drug interactions: David Back, UK |
|
10:40-11:00 |
Panel discussion |
|
|
|
11:00-11:30 |
Coffee Break |
|
|
|
SESSION 3: DO WE NEED TO KNOW GENETIC FACTORS SUCH AS IL28B FOR TREATMENT DECISION MAKING? (parallel session) |
HALL A | |
|
Moderator: Christoph Sarrazin, Germany |
|
11:30-11:45 |
Yes: Vincent Soriano, Spain |
|
11:45-12:00 |
No: Mathew Albert, France |
|
12:00-12:15 |
Discussion |
|
|
| SESSION 4: HCV THERAPY IS FOR SPECIALISTS ONLY? (parallel session) |
HALL B | |
|
Moderator: Geoffrey Dusheiko, Germany |
|
11:30-11:45 |
Yes: Marion Peters, USA |
|
11:45-12:00 |
No: Michael Biermer, Germany |
|
12:00-12:15 |
Discussion |
|
|
|
12:15-13:00 |
Lunch Break |
|
|
|
13:00-14:15 |
|
Merck Sharp & Dohme Satellite Symposium
Successful HCV Treatment in the Real World: Lessons From Clinical Practice
Chairperson: Jürgen Rockstroh, Germany |
HALL A | |
|
13:00-13:05 |
Welcome and Opening Remarks: Jürgen Rockstroh, Germany |
|
13:05-13:20 |
Emerging Evidence Guiding Clinical Practice: Christoph Sarrazin, Germany |
|
13:20-13:40 |
Optimizing Outcomes with Protease Inhibitors: Adverse Events Management and Prevention of Resistance: Jean Michel Pawlotsky, France |
|
13:40-14:00 |
Protease Inhibitors in Practice:Case Studies: Geoffrey Dusheiko, UK |
|
14:00-14:10 |
Panel Discussion |
|
14:10-14:15 |
Closing Remarks: Jürgen Rockstroh, Germany |
|
|
|
|
HEPATITIS: STATE OF THE ART CLINICAL CARE |
|
Moderators: Marion Peters, USA & Massimo Puoti, Italy |
|
14:15-14:35 |
Fatty liver disease: what do we know? Claus Niederau, Germany |
|
14:35-14:55 |
Vitamin D and liver disease: Which role does it play? Christian M. Lange, Germany |
|
14:55-15:15 |
End-stage liver disease: What is new? Marion Peters, USA |
|
15:15-15:35 |
Treatment of HCC: state of the Art: Massimo Puoti, Italy |
|
15:35-15:45 |
Panel Discussion |
|
|
|
15:45-16:15 |
Coffee Break and Poster Prize Ceremony |
|
|
|
SESSION 6 (parallel session) |
HALL A | |
|
SHOULD PATIENTS WAIT FOR DAA COMBINATION THERAPY |
|
Moderator: Vincent Soriano, Spain |
|
16:15-16:30 |
Yes: Patrick Ingiliz , Germany |
|
16:30-16:45 |
No: Geoffrey Dusheiko, UK |
|
16:45-17:00 |
Discussion |
|
16:00-17:00 |
|
SESSION 7 (parallel session) |
HALL B | |
|
|
RESISTANCE TO HCV PROTEASE INHIBITORS: GAME OVER? |
|
Moderator: Jonathan M. Schapiro , Israel |
|
|
Yes: Jean Michel Pawlotsky , France |
|
16:30-16:45 |
Yes: Christoph Sarrazin , Germany |
|
16:45-17:00 |
Discussion |
|
17:00-17:30 |
|
SESSION 8 (parallel session)
INTERACTIVE CASE SESSION: HOW TO TREAT HCV RELAPSE AFTER LIVER TRANSPLANT |
HALL A | |
|
|
Case discussion: How to treat HCV relapse after OLTX |
|
|
|
|
17:00-17:30 |
|
SESSION 9 (parallel session)
INTERACTIVE CASE SESSION: HOW TO TREAT HCV IN HIV COINFECTION
Supported by an unrestricted grant from Boehringer Ingelheim |
HALL B | |
|
|
Case discussion: How to treat HCV in HIV coinfection |
|
|
Stefan Mauss , Germany |
|
Saturday, October 20, 2012 |
|
08:30-10:30 |
| PLENARY SESSION 10: HBV THERAPY IN 2012 |
HALL A | |
|
Moderators: Fabien Zoulim, France & Jörg Petersen, Germany |
|
08:30-08:35 |
Overview of HBV sessions by HBV Program Director: Fabien Zoulim, France |
|
08:35-09:00 |
Hepatitis B Therapy: State of the Art and open challenges: Jörg Petersen, Germany |
|
Is there a need for combination therapy? |
|
09:00-09:15 |
Yes: Florian van Boemmel, Germany |
|
09:15-09:30 |
No: Maria Buti, Spain |
|
09:30-09:50 |
HBV preventive and therapeutic vaccines: What is new? Marie-Louise Michel, France |
| 09:50-10:10 |
Hepatitis Delta: What is new? Heiner Wedemeyer, Germany |
|
10:10-10:30 |
Panel Discussion |
|
|
|
10:30-11:00 |
Coffee Break |
|
11:00-11:45 |
|
PLENARY SESSION 11:
INTERACTIVE CASE SESSION AND DISCUSSION: THE CHALLENGING HEPATITIS B CASE
Supported by an unrestricted grant from Gilead Sciences Europe Ltd. |
HALL A | |
|
Moderator: Fabien Zoulim , France |
|
Mark Nelson, UK |
|
Karine Lacombe, France |
|
|
| PLENARY SESSION 12 |
HALL A | HCV-Looking to the Future |
|
Moderator: Mark Thursz, UK & Jürgen Rockstroh, Germany |
|
11:45-12:05 |
Strategies to prevent HCC: What can we do? Mark Thursz, UK |
|
12:05-12:20 |
Can we afford HCV DAAs for all? Maud Lemoine, France |
|
12:20-12:45 |
What are the remaining challenges in hepatitis research? Michael Manns, Germany |
| 12:45-13:00 |
Farewell Toast |
|
|
|
|
WebStudio.co.il